Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales

Core Insights - Immuron Limited (NASDAQ:IMRN) reported a 49% growth in global revenue for fiscal year 2025, primarily driven by strong sales of its flagship product, Travelan [1][2] - The company achieved a net loss reduction of 24% year-over-year, with a loss per share of A$0.023 for FY2025, an improvement from A$0.03 in FY2024 [2] - Gross margins remained robust at 65.4%, indicating strong profitability despite the losses [2] Revenue Performance - North American sales for Travelan increased by 76% to A$2 million, attributed to growth in Amazon and Canadian retail [1] - Australian sales rose 40% to A$5.3 million, supported by the introduction of new pharmacy channels [1] Financial Position - At year-end, Immuron held AU$2.83 million in cash, a decrease from AU$11.66 million the previous year [2] - Shareholders' equity decreased to AU$8 million from AU$12.7 million in 2024, reflecting a decline in overall financial strength [2] - The company maintained minimal long-term debt, indicating a stable balance sheet [2]